Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance

Immune checkpoint inhibitors (ICIs), although promising, have variable benefit in head and neck cancer (HNC). We noted that tumor galectin-1 (Gal1) levels were inversely correlated with treatment response and survival in patients with HNC who were treated with ICIs. Using multiple HNC mouse models,...

詳細記述

保存先:
書誌詳細
出版年:J Clin Invest
主要な著者: Nambiar, Dhanya K., Aguilera, Todd, Cao, Hongbin, Kwok, Shirley, Kong, Christina, Bloomstein, Joshua, Wang, Zemin, Rangan, Vangipuram S., Jiang, Dadi, von Eyben, Rie, Liang, Rachel, Agarwal, Sonya, Colevas, A. Dimitrios, Korman, Alan, Allen, Clint T., Uppaluri, Ravindra, Koong, Albert C., Giaccia, Amato, Le, Quynh Thu
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Clinical Investigation 2019
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6877340/
https://ncbi.nlm.nih.gov/pubmed/31710313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129025
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料